Sutro Biopharma – $85 Million IPO

Cooley advised the underwriters on Sutro Biopharma, Inc.’s $85 million initial public offering of 5,667,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 850,050 shares. Partners Dave Peinsipp, Charlie Kim and Drew Williamson led the Cooley team advising the underwriters.

Cowen and Piper Jaffray acted as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow acted as co-managers.

Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders. The company’s shares now trade on the Nasdaq Global Market under the symbol “STRO.”

Related Contacts
David Peinsipp Partner, San Francisco
Charlie Kim Partner, San Diego
Drew Williamson Partner, San Francisco
Kristin VanderPas Partner, San Francisco
Denny Won Associate, San Francisco
Christopher Wong Associate, San Francisco
Alla Kagan Paralegal Specialist, San Diego
Related Practices & Industries

Capital Markets Public Companies Life Sciences